Key facts
- Julie’s last known valuation is $40.0M.
- It has raised $8.5M; the latest was Early Stage VC ($5.0M) in Nov 2024.
- Notable investors include Western Technology Investment, GingerBread Capital, G9 Ventures, Ingeborg Investments, Align Ventures — 15 tracked in total.
- Status: Privately Held (backing).
- ·The complete investor list — 15 names
- ·Watchlist + deal alerts for Julie
- ·The full record, as it builds
Funding rounds
No funding rounds for Julie are on record yet — either the company hasn't raised institutional capital, or the raise hasn't surfaced in our sources.
About Julie
Developer of emergency contraception medicine intended to stop a pregnancy before it starts. The company's medicine is an active ingredient, levonorgestrel, which helps prevent pregnancy by temporarily delaying or stopping ovulation, enabling women with a morning-after pill and editorial and education-based narrative and content around well-being.
- Sector
- Healthcare
- HQ
- Romeoville, IL, United States
- Founded
- 2021
- Employees
- 10
- Website
- juliecare.co/
- Ownership
- Privately Held (backing)
Julie doesn't have a composite mark yet — a PA Mark is published once enough pricing inputs exist (trade prints, fund marks, round prices). The rest of the record below builds toward it.
Recorded secondary trades
No secondary trades in Julie shares have been recorded yet. When a print lands — third-party, direct report, or platform — it appears here with structure, source, and price.
Institutional fund marks
No SEC-registered fund has reported a fair-value mark on Julie in its N-PORT filings yet. We sweep new filings monthly.